All treatments
Treatment
Pembrolizumab 25 MG/ML [Keytruda] clinical trials
2 indexed studies · 1 currently recruiting
- Active not recruitingPHASE2
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
This study looks at new treatments for recurrent ovarian cancer that has responded to previous platinum-based chemotherapy. It compares a vaccine (OSE2101) alone, or with another drug (Pembrolizumab), against standard supportive care to see if they can delay the cancer returning.
For: Platinum-sensitive Ovarian Cancer · Relapsed Ovarian CancerBelgium · France · Germany - RecruitingPHASE3
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This study looks at treating advanced lung cancer (non-small cell) with a drug called pembrolizumab (Keytruda). After 6 months of standard treatment, it aims to see if giving the drug less often is just as safe and effective, potentially making treatment easier for patients and saving money for the NHS.
For: Lung Cancer, Nonsmall CellUnited Kingdom